Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carrimycin - Shenyang Tonglian Group

Drug Profile

Carrimycin - Shenyang Tonglian Group

Alternative Names: Biotechmycin; Biotechspiramycin; Levocarrimycin

Latest Information Update: 04 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenyang Tonglian Group
  • Class Antibacterials; Macrolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Head and neck cancer
  • Phase 0 Sepsis
  • Clinical Phase Unknown Pneumonia

Most Recent Events

  • 25 Apr 2020 Phase-0 clinical trials in Sepsis in China (PO) (ChiCTR2000032339)
  • 15 Feb 2020 Clinical trials in Pneumonia in China (unspecified route) (ChiCTR2000029867) (NCT04286503)
  • 19 Dec 2019 Phase-I clinical trials in Head and neck cancer (Late-stage disease, Metastatic disease, Recurrent) in China (PO) (NCT04413214)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top